Thrombophilia bloodwork
PreclinicalBiologic
Thrombophilia bloodwork is one of 8 biologic programs targeting Antiphospholipid Syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Antiphospholipid Syndrome
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Coumadin
AAbbott
Approved
Rapamune
PPrism Pharmaceuticals
Phase 2
Brukinsa
BBeOne Medicines
Phase 2
Blood Withdrawn
Emergent BioSolutionsPreclinical
Blood Redrawal
CCentre Hospitalier Universitaire, Amiens
Preclinical
Drug Inducing Myocarditis
GGroupe Hospitalier Pitie-Salpetriere
Preclinical
Thrombophilia bloodwork
CCentre Hospitalier Universitaire de Nīmes
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antiphospholipid Syndrome1 trial
Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome
Terminated·—·N/A·NCT01649479·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thrombophilia bloodwork. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details